Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00350882 | Colorectum | MSS | establishment or maintenance of apical/basal cell polarity | 20/3467 | 49/18723 | 2.36e-04 | 3.24e-03 | 20 |
GO:00612452 | Colorectum | MSS | establishment or maintenance of bipolar cell polarity | 20/3467 | 49/18723 | 2.36e-04 | 3.24e-03 | 20 |
GO:00071602 | Colorectum | MSS | cell-matrix adhesion | 65/3467 | 233/18723 | 2.77e-04 | 3.67e-03 | 65 |
GO:00015582 | Colorectum | MSS | regulation of cell growth | 105/3467 | 414/18723 | 2.97e-04 | 3.90e-03 | 105 |
GO:00604431 | Colorectum | MSS | mammary gland morphogenesis | 18/3467 | 43/18723 | 3.30e-04 | 4.24e-03 | 18 |
GO:00467772 | Colorectum | MSS | protein autophosphorylation | 63/3467 | 227/18723 | 3.96e-04 | 4.91e-03 | 63 |
GO:00422542 | Colorectum | MSS | ribosome biogenesis | 79/3467 | 299/18723 | 4.32e-04 | 5.23e-03 | 79 |
GO:00615642 | Colorectum | MSS | axon development | 115/3467 | 467/18723 | 5.33e-04 | 6.00e-03 | 115 |
GO:00300422 | Colorectum | MSS | actin filament depolymerization | 22/3467 | 59/18723 | 5.35e-04 | 6.02e-03 | 22 |
GO:00017631 | Colorectum | MSS | morphogenesis of a branching structure | 55/3467 | 196/18723 | 6.70e-04 | 7.25e-03 | 55 |
GO:00308342 | Colorectum | MSS | regulation of actin filament depolymerization | 20/3467 | 54/18723 | 1.04e-03 | 1.03e-02 | 20 |
GO:0061138 | Colorectum | MSS | morphogenesis of a branching epithelium | 51/3467 | 182/18723 | 1.06e-03 | 1.05e-02 | 51 |
GO:00310322 | Colorectum | MSS | actomyosin structure organization | 53/3467 | 196/18723 | 2.04e-03 | 1.75e-02 | 53 |
GO:00075892 | Colorectum | MSS | body fluid secretion | 29/3467 | 93/18723 | 2.21e-03 | 1.84e-02 | 29 |
GO:00485881 | Colorectum | MSS | developmental cell growth | 61/3467 | 234/18723 | 2.56e-03 | 2.03e-02 | 61 |
GO:00605601 | Colorectum | MSS | developmental growth involved in morphogenesis | 61/3467 | 234/18723 | 2.56e-03 | 2.03e-02 | 61 |
GO:0060444 | Colorectum | MSS | branching involved in mammary gland duct morphogenesis | 10/3467 | 22/18723 | 3.42e-03 | 2.56e-02 | 10 |
GO:0006364 | Colorectum | MSS | rRNA processing | 58/3467 | 225/18723 | 4.17e-03 | 3.03e-02 | 58 |
GO:0060603 | Colorectum | MSS | mammary gland duct morphogenesis | 12/3467 | 30/18723 | 5.00e-03 | 3.46e-02 | 12 |
GO:0016072 | Colorectum | MSS | rRNA metabolic process | 60/3467 | 236/18723 | 5.01e-03 | 3.46e-02 | 60 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DR1 | SNV | Missense_Mutation | novel | c.25N>A | p.Asp9Asn | p.D9N | Q01658 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
DR1 | SNV | Missense_Mutation | | c.145N>A | p.Leu49Ile | p.L49I | Q01658 | protein_coding | deleterious(0.02) | probably_damaging(0.92) | TCGA-CA-6715-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
DR1 | SNV | Missense_Mutation | | c.146N>G | p.Leu49Arg | p.L49R | Q01658 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DR1 | SNV | Missense_Mutation | | c.328N>C | p.Asn110His | p.N110H | Q01658 | protein_coding | tolerated(0.08) | benign(0.222) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
DR1 | SNV | Missense_Mutation | novel | c.253N>G | p.Ser85Gly | p.S85G | Q01658 | protein_coding | tolerated(0.29) | benign(0.04) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DR1 | SNV | Missense_Mutation | | c.161N>T | p.Ala54Val | p.A54V | Q01658 | protein_coding | deleterious(0.02) | possibly_damaging(0.668) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DR1 | SNV | Missense_Mutation | novel | c.41C>T | p.Pro14Leu | p.P14L | Q01658 | protein_coding | deleterious(0) | possibly_damaging(0.618) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DR1 | SNV | Missense_Mutation | rs182894486 | c.403G>A | p.Glu135Lys | p.E135K | Q01658 | protein_coding | tolerated(0.16) | possibly_damaging(0.522) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
DR1 | SNV | Missense_Mutation | | c.472G>A | p.Ala158Thr | p.A158T | Q01658 | protein_coding | tolerated(0.38) | probably_damaging(0.956) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DR1 | SNV | Missense_Mutation | | c.516N>A | p.Asp172Glu | p.D172E | Q01658 | protein_coding | tolerated_low_confidence(0.32) | benign(0) | TCGA-D1-A176-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |